NO308539B1 - Konjugat, anvendelse av konjugat, samt farmasøytisk blanding som omfatter et konjugat - Google Patents

Konjugat, anvendelse av konjugat, samt farmasøytisk blanding som omfatter et konjugat Download PDF

Info

Publication number
NO308539B1
NO308539B1 NO922383A NO922383A NO308539B1 NO 308539 B1 NO308539 B1 NO 308539B1 NO 922383 A NO922383 A NO 922383A NO 922383 A NO922383 A NO 922383A NO 308539 B1 NO308539 B1 NO 308539B1
Authority
NO
Norway
Prior art keywords
antibody
ricin
target cell
residue
toxin
Prior art date
Application number
NO922383A
Other languages
English (en)
Norwegian (no)
Other versions
NO922383L (no
NO922383D0 (no
Inventor
Andrew Firman Wright
David Charles Blakey
John Edward Fitton
Leif Lindholm
Peter Lind
Jan Holmgren
Original Assignee
Zeneca Ltd
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd, Kabi Pharmacia Ab filed Critical Zeneca Ltd
Publication of NO922383D0 publication Critical patent/NO922383D0/no
Publication of NO922383L publication Critical patent/NO922383L/no
Publication of NO308539B1 publication Critical patent/NO308539B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44Antibodies bound to carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Semiconductor Lasers (AREA)
  • Bipolar Transistors (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO922383A 1991-07-03 1992-06-17 Konjugat, anvendelse av konjugat, samt farmasøytisk blanding som omfatter et konjugat NO308539B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919114399A GB9114399D0 (en) 1991-07-03 1991-07-03 Conjugates

Publications (3)

Publication Number Publication Date
NO922383D0 NO922383D0 (no) 1992-06-17
NO922383L NO922383L (no) 1993-01-04
NO308539B1 true NO308539B1 (no) 2000-09-25

Family

ID=10697775

Family Applications (1)

Application Number Title Priority Date Filing Date
NO922383A NO308539B1 (no) 1991-07-03 1992-06-17 Konjugat, anvendelse av konjugat, samt farmasøytisk blanding som omfatter et konjugat

Country Status (24)

Country Link
EP (1) EP0528527B1 (de)
JP (1) JP3735379B2 (de)
KR (1) KR100252147B1 (de)
AT (1) ATE164768T1 (de)
AU (1) AU665546B2 (de)
CA (1) CA2073113C (de)
CZ (1) CZ209792A3 (de)
DE (1) DE69225035T2 (de)
DK (1) DK0528527T3 (de)
ES (1) ES2113923T3 (de)
FI (1) FI106928B (de)
GB (2) GB9114399D0 (de)
GR (1) GR3026575T3 (de)
HU (1) HU215243B (de)
IE (1) IE922190A1 (de)
IL (1) IL102399A (de)
MY (1) MY110513A (de)
NO (1) NO308539B1 (de)
NZ (1) NZ243437A (de)
PT (1) PT100660B (de)
SK (1) SK209792A3 (de)
TW (1) TW329425B (de)
ZA (1) ZA924973B (de)
ZW (1) ZW10192A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
ATE68703T1 (de) 1984-02-08 1991-11-15 Cetus Corp Toxinkonjugate.
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
DE69122777T2 (de) * 1990-07-20 1997-04-10 Pharmacia & Upjohn Ab, Stockholm Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation

Also Published As

Publication number Publication date
GB9114399D0 (en) 1991-08-21
JP3735379B2 (ja) 2006-01-18
JPH05320065A (ja) 1993-12-03
FI106928B (fi) 2001-05-15
TW329425B (en) 1998-04-11
AU1943092A (en) 1993-01-07
MY110513A (en) 1998-07-31
EP0528527B1 (de) 1998-04-08
IL102399A (en) 2003-05-29
CA2073113A1 (en) 1993-01-04
DK0528527T3 (da) 1999-01-18
ZW10192A1 (en) 1993-03-31
ZA924973B (en) 1993-04-28
IE922190A1 (en) 1993-01-13
ES2113923T3 (es) 1998-05-16
IL102399A0 (en) 1993-01-14
SK209792A3 (en) 1994-06-08
PT100660A (pt) 1993-10-29
ATE164768T1 (de) 1998-04-15
CA2073113C (en) 2004-09-14
EP0528527A2 (de) 1993-02-24
NZ243437A (en) 1994-10-26
HU9202219D0 (en) 1992-10-28
FI923085A0 (fi) 1992-07-03
NO922383L (no) 1993-01-04
DE69225035D1 (de) 1998-05-14
EP0528527A3 (en) 1993-03-17
DE69225035T2 (de) 1998-08-13
KR100252147B1 (ko) 2000-09-01
GB9212880D0 (en) 1992-07-29
PT100660B (pt) 1999-06-30
HU215243B (hu) 1998-11-30
GR3026575T3 (en) 1998-07-31
KR930001928A (ko) 1993-02-22
CZ209792A3 (en) 1993-01-13
AU665546B2 (en) 1996-01-11
NO922383D0 (no) 1992-06-17
FI923085L (fi) 1993-01-04
HUT67048A (en) 1995-01-30

Similar Documents

Publication Publication Date Title
US5840840A (en) Selective RNase cytotoxic reagents
AU2022291603B2 (en) Anti-CD123 antibodies and conjugates and derivatives thereof
US5744580A (en) Immunotoxins comprising ribosome-inactivating proteins
ES2214494T3 (es) Estructuras de fijacion dirigidas contra el antigeno ca55.1.
US11679162B2 (en) Anti-5T4 antibody-drug conjugate and use thereof
EP2917243B1 (de) Die beta-haarnadel von her3 bindende her3-antikörper
WO1985003508A1 (en) Toxin conjugates
JP6537970B2 (ja) Her3のベータヘアピン及びher4のベータヘアピンに結合する抗her3/her4抗原結合タンパク質
JP2008520186A (ja) 哺乳類eag1イオンチャネルタンパク質に対する新規の抗体
AU2022335573A9 (en) Anti-nectin-4 antibody, drug conjugate, and preparation method therefor and use thereof
JPS61501449A (ja) 毒素複合体
NO321548B1 (no) Monoklonalt antistoff som binder seg til GA733-1-antigen, hybridom, konjugat, humant/muse-rekombinant antistoff, nukleinsyremolekyl, plasmid, vertsvektorsystem samt fremgangsmate for fremstilling av et protein.
WO2022001864A1 (zh) 一种抗体-药物偶联物,其制备方法及应用
Hoogenboom et al. Cloning and expression of a chimeric antibody directed against the human transferrin receptor.
JPH09509043A (ja) 植物ブリオニア・ディオイカから単離された新規なリボソーム不活性化タンパク質
WO1992015327A1 (en) Recombinant double chain immunotoxins
TW201605902A (zh) 結合HER3之β-髮夾結構的抗HER3抗體
EP0739984A1 (de) Bivalente Polypeptiden die mindestens zwei Bereichen enthalten
NO308539B1 (no) Konjugat, anvendelse av konjugat, samt farmasøytisk blanding som omfatter et konjugat
JP2024534681A (ja) 抗cd39抗体ー薬物複合体及びその使用
CN115210262A (zh) 人源化抗-cd22重组免疫毒素及其应用
US11020490B2 (en) Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit
ES2241268T3 (es) Onconasa recombinante y proteinas de fusion de onconasa recombinante.
Walsh et al. UNIVERSITY OF CAMBRIDGE

Legal Events

Date Code Title Description
MK1K Patent expired